These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33116697)

  • 1. Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand.
    Permsuwan U; Phrommintikul A; Silavanich V
    Clinicoecon Outcomes Res; 2020; 12():579-588. PubMed ID: 33116697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.
    Krittayaphong R; Yadee J; Permsuwan U
    Clinicoecon Outcomes Res; 2019; 11():767-777. PubMed ID: 31824183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.
    Bertoldi EG; Rohde LE; Zimerman LI; Pimentel M; Polanczyk CA
    Int J Cardiol; 2013 Mar; 163(3):309-315. PubMed ID: 21704396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand.
    Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
    Clinicoecon Outcomes Res; 2022; 14():487-498. PubMed ID: 35909499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of transcatheter aortic valve implantation versus surgery in severe aortic stenosis patients with intermediate surgical risk in Thailand.
    Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
    J Geriatr Cardiol; 2022 Nov; 19(11):822-832. PubMed ID: 36561052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
    Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
    Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
    Krittayaphong R; Permsuwan U
    Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand.
    Arunmanakul P; Chaiyakunapruk N; Phrommintikul A; Ruengorn C; Permsuwan U
    J Am Pharm Assoc (2003); 2022; 62(1):71-78. PubMed ID: 34756525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
    Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
    Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
    BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.
    Poggio R; Augustovsky F; Caporale J; Irazola V; Miriuka S
    Int J Technol Assess Health Care; 2012 Oct; 28(4):429-35. PubMed ID: 23006489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.